RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Led by pioneers in synthetic biology, gene editing and single-cell sequencing technologies, their team is developing next generation technologies to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/30/18 | $7,000,000 | Seed |
Baidu Ventures Nest.Bio Ventures Sequoia China  Volcanics Ventures | undisclosed |
| 01/07/20 | $11,000,000 | Series A |
Baidu Ventures Nest.Bio Ventures Oriza Seed Sequoia China Volcanics Ventures | undisclosed |
